The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryopoor plasma

Thomas J. Raife, Kenneth D. Friedman, Denis M. Dwyre

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care. A widely held historical model of TTP microvascular thrombosis implicated circulating ultralarge von Willebrand factor (ULVWF) in causing spontaneous platelet (PLT) aggregation. From this pathogenic model, concerns about ULVWF in fresh-frozen plasma (FFP) used to treat patients led to widespread use of cryopoor plasma (CPP) as an alternative. There is scant evidence, however, that circulating ULVWF contributes to microvascular thrombosis in TTP. New evidence suggests that the formation of PLT aggregates in TTP may be mediated by VWF in the process of being released from endothelium. Moreover, clinical studies do not demonstrate superior efficacy of CPP compared to FFP in the treatment of TTP. Because CPP may have reduced concentrations of factors important in the treatment of TTP, including ADAMTS13 metalloprotease, a reappraisal of the use of CPP in the treatment of TTP is warranted.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalTransfusion
Volume46
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Thrombotic Thrombocytopenic Purpura
von Willebrand Factor
Virulence
Therapeutics
Thrombosis
Metalloproteases
Endothelium
Patient Care
Blood Platelets

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura : Reconsideration of treatment with cryopoor plasma. / Raife, Thomas J.; Friedman, Kenneth D.; Dwyre, Denis M.

In: Transfusion, Vol. 46, No. 1, 01.2006, p. 74-79.

Research output: Contribution to journalArticle

@article{b262a598128d46bfb23382a4081d1b29,
title = "The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryopoor plasma",
abstract = "New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care. A widely held historical model of TTP microvascular thrombosis implicated circulating ultralarge von Willebrand factor (ULVWF) in causing spontaneous platelet (PLT) aggregation. From this pathogenic model, concerns about ULVWF in fresh-frozen plasma (FFP) used to treat patients led to widespread use of cryopoor plasma (CPP) as an alternative. There is scant evidence, however, that circulating ULVWF contributes to microvascular thrombosis in TTP. New evidence suggests that the formation of PLT aggregates in TTP may be mediated by VWF in the process of being released from endothelium. Moreover, clinical studies do not demonstrate superior efficacy of CPP compared to FFP in the treatment of TTP. Because CPP may have reduced concentrations of factors important in the treatment of TTP, including ADAMTS13 metalloprotease, a reappraisal of the use of CPP in the treatment of TTP is warranted.",
author = "Raife, {Thomas J.} and Friedman, {Kenneth D.} and Dwyre, {Denis M.}",
year = "2006",
month = "1",
doi = "10.1111/j.1537-2995.2005.00674.x",
language = "English (US)",
volume = "46",
pages = "74--79",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura

T2 - Reconsideration of treatment with cryopoor plasma

AU - Raife, Thomas J.

AU - Friedman, Kenneth D.

AU - Dwyre, Denis M.

PY - 2006/1

Y1 - 2006/1

N2 - New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care. A widely held historical model of TTP microvascular thrombosis implicated circulating ultralarge von Willebrand factor (ULVWF) in causing spontaneous platelet (PLT) aggregation. From this pathogenic model, concerns about ULVWF in fresh-frozen plasma (FFP) used to treat patients led to widespread use of cryopoor plasma (CPP) as an alternative. There is scant evidence, however, that circulating ULVWF contributes to microvascular thrombosis in TTP. New evidence suggests that the formation of PLT aggregates in TTP may be mediated by VWF in the process of being released from endothelium. Moreover, clinical studies do not demonstrate superior efficacy of CPP compared to FFP in the treatment of TTP. Because CPP may have reduced concentrations of factors important in the treatment of TTP, including ADAMTS13 metalloprotease, a reappraisal of the use of CPP in the treatment of TTP is warranted.

AB - New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care. A widely held historical model of TTP microvascular thrombosis implicated circulating ultralarge von Willebrand factor (ULVWF) in causing spontaneous platelet (PLT) aggregation. From this pathogenic model, concerns about ULVWF in fresh-frozen plasma (FFP) used to treat patients led to widespread use of cryopoor plasma (CPP) as an alternative. There is scant evidence, however, that circulating ULVWF contributes to microvascular thrombosis in TTP. New evidence suggests that the formation of PLT aggregates in TTP may be mediated by VWF in the process of being released from endothelium. Moreover, clinical studies do not demonstrate superior efficacy of CPP compared to FFP in the treatment of TTP. Because CPP may have reduced concentrations of factors important in the treatment of TTP, including ADAMTS13 metalloprotease, a reappraisal of the use of CPP in the treatment of TTP is warranted.

UR - http://www.scopus.com/inward/record.url?scp=33644833901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644833901&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2005.00674.x

DO - 10.1111/j.1537-2995.2005.00674.x

M3 - Article

C2 - 16398733

AN - SCOPUS:33644833901

VL - 46

SP - 74

EP - 79

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 1

ER -